SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. today announced the relocation of the Company’s corporate headquarters and research laboratories to San Diego. The new facility will be in the Sorrento Valley and will house the Company’s research, preclinical and clinical development, pharmaceutical sciences and administrative operations.
“Moving our two southern California facilities to San Diego’s biotechnology corridor is integral to our future growth and success, uniting the organization while providing access to a wealth of biotechnology and pharmaceutical industry expertise,” said Barry D. Quart, PharmD, Ardea Biosciences’ President and CEO. “We look forward to becoming an important contributor to the San Diego community at large.”
Employees from both southern California locations will be relocating to our new facility and additional career opportunities can be found on the “Careers” page of the Company’s website at http://www.ardeabio.com. For additional career related information please email careers@ardeabio.com.
About Ardea Biosciences, Inc.
Ardea Biosciences of San Diego, California is a biotechnology company focused on the discovery and development of small-molecule therapeutics in virology, oncology and inflammation. The Company has two product candidates in clinical development and several others in preclinical development. Ardea’s most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company’s lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory diseases. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea’s goals, including the expected properties and benefits of RDEA806 and RDEA119 and its other compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea’s most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings “Risk Factors.” All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Edie DeVine of WeissComm Partners, +1-415-946-1081, for Ardea
Biosciences, Inc.
Web site: http://www.ardeabio.com/
